Videos

Explore the criteria for considering doublet or triplet therapies in advanced prostate cancer, examining their potential benefits and minimal added toxicity as discussed by key opinion leaders.

Hayder Saeed, MD, discusses how the mechanism of action of tafasitamab makes the therapy a potent cancer cell killer for patients with diffuse large B-cell lymphoma.

Tracy Proverbs-Singh, MD, and Steven Lee-Kong, MD, reflect on how to incorporate sequencing and personalized treatments effectively in oncology practice.

Key opinion leaders explore the evolving landscape of precision medicine in gastrointestinal cancers and how molecular profiling is transforming treatment decisions for patients.

Joan Culpepper-Morgan, MD, provides an overview on different treatment approaches for patients with hepatocellular carcinoma.

Joshua K. Sabari, MD, discusses where research on LY3537982 for patients with KRAS G12C-mutant advanced solid tumors is headed.

Matthew Powell, MD, discusses next steps and unmet needs following the phase 3 RUBY/ENGOT-EN6 study and the FDA approval of dostarlimab in combination with chemotherapy for the treatment of patients with mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer.

Key opinion leaders review the evolving landscape of metastatic HSPC, exploring the benefits and considerations of triplet combination therapies, including chemotherapy and ARPI agents.

David Morris, MD, FACS, and Benjamin Garmezy, MD, discuss treatment options, including ARPIs like enzalutamide and darolutamide, in nmCRPC, emphasizing the importance of personalized approaches for patient quality of life and outcome improvement.

In a discussion with Targeted Oncology, David Dingli, MD, PhD, looks at how the use of step-up dosing with tecalistimab helped avoid many serious adverse events.

Adam J. Olszewski, MD, discusses findings from a phase 1b/2 study which evaluated treatment with mosunetuzumab for the treatment of elderly/unfit patients who were previously untreated for their diffuse large B-cell lymphoma.

Adam Brufsky, MD, PhD, FACP, discusses background and next steps of the phase 3 PALOMA-2 study which evaluated palbociclib plus letrozole in patients that identified as Black or Hispanic with advanced breast cancer.

Dr Fonseca discusses the prognosis of a patient with relapsed/refractory multiple myeloma, noting the patient's history with treatments like venetoclax and dexamethasone, and the ultimate decision to switch to talquetamab, a GPRC5D-directed bispecific antibody.

Rafael Fonseca, MD, presents the clinical case of a 66-year-old man with relapsed/refractory multiple myeloma for review.

Hussein Tawbi, MD, PhD, explains that for patients with melanoma without a BRAF mutation, first-line therapies primarily include immunotherapy-based (IO) checkpoint inhibitors, with PD-1 inhibitor combination therapies being the current standard of care.

Hussein Tawbi, MD, PhD, highlights the importance of BRAF mutations and LDH levels in diagnosing patients with metastatic melanoma and guiding treatment.

Elizabeth Lihua Budde, MD, PhD, breaks down the design and baseline characteristics of the phase 3 POLARIX trial that led to the approval of polatuzumab in combination with R-CHP for certain patients with diffuse large B-cell lymphoma.

Lisa B. Ercolano, MD, discusses some of the advances that have been seen in the treatment of sarcomas.

Shared insight into the latest developments in immunotherapy and novel treatment options for colorectal cancer, including ongoing trials and the pursuit of new targets to enhance the immune response against cancer.

Tracy Proverbs-Singh, MD, and Steven Lee-Kong, MD, explore the forefront of colorectal cancer treatment, featuring targeted therapies, immunotherapy options, and the power of multidisciplinary teamwork.

Lindsey S. Treviño, PhD, discusses some of the disparities that currently exist among patients with cancer.

Jorge E. Cortes, MD, discusses the safety profile of olutasidenib for the treatment of patients with relapsed/refractory acute myeloid leukemia that harbor an IDH1 mutation.

Insight into the expanding landscape of hormone therapies, including androgen receptor inhibitors and biosynthesis inhibitors, and their diverse applications in prostate cancer treatment.

Key opinion leader Benjamin Garmezy, MD, discusses the shifting landscape of prostate cancer management, the importance of identifying lethal cases, and the challenges in risk stratification and prognosis.

Thomas Powles, MD, MBBS, MRCP, discusses findings from the phase 3 EV-302 clinical trial of enfortumab vedotin-ejfv with pembrolizumab vs chemotherapy for the treatment of patients with previously untreated locally advanced or metastatic urothelial cancer.

Tina Cascone, MD, PhD, discusses the main findings from the phase 3 CheckMate-77T trial of a nivolumab-based regimen for the treatment of patients with stage IIA to IIIB non–small cell lung cancer.

Manmeet Ahluwalia, MD, discusses what early results from the CRUX trial of ruxolitinib for the treatment of patients with newly-diagnosed high-grade gliomas may mean for future research.

Dan T. Vogl, MD, MSCE, discusses the mechanism of action of modakafusp alfa for the treatment of patients with relapsed or refractory multiple myeloma.

Discover how the treatment landscape for relapsed/refractory myeloma is evolving through collaboration between academic centers and community oncologists, offering patients access to innovative therapies and clinical trials.